on IL-1β and TNF-α. Herein, 36 novel derivatives were designed and synthesized, and nearly half of the derivatives exhibited much better selectivity on IL-1β releasement inhibition as well as keep similar inhibitory activities to lead compound. In 20 μM, compound 19 exhibited IL-1β releasement inhibitory activity (IC50 = 5.489 μM) which closed to the original compound, and 4.5-fold superior selectivity
炎症和免疫与多种免疫疾病的发生发展密切相关。虽然IL-1β已被确定为许多免疫疾病的关键细胞因子,但临床上仍缺乏安全、特异性的小分子IL-1β释放
抑制剂,亟需临床应用。三唑的研究前景受限于其复杂的药理作用,对IL-1β和TNF-α的作用较差。在此,设计和合成了 36 种新型衍
生物,其中近一半的衍
生物对 IL-1β 释放抑制具有更好的选择性,并保持与先导化合物相似的抑制活性。在 20 μM 中,化合物19表现出 IL-1β 释放抑制活性(IC 50 = 5.489 μM),接近原始化合物,比先导化合物 (SI = 0.82) 高 4.5 倍的选择性 (SI = 4.71)。还提出了一种可能的三唑衍
生物对 IL-1β 释放抑制和选择性的
SAR 模型,这可能会促进未来发现更有效和特异性的 IL-1β 释放
抑制剂。